Lupus drug market growing as physicians adopt newer options — and look for more, research finds

09 Jan 2024

Cell TherapyImmunotherapyPhase 2

With three relatively new drugs, plus a busy pipeline in both systemic lupus erythematosus (SLE) and lupus nephritis (LN), the lupus market has been taking off. The LN arena is especially busy now with two competitors gaining steam, but SLE is also on physicians’ minds with the potential for CAR-T cell therapy treatment on the horizon, according to research from Spherix Global Insights. While lupus CAR-T studies have been around for a few years, the potential for now almost a dozen in development, mostly in Phase I or Phase II studies for both SLE and LN, is generating some excitement among physicians, said Spherix senior insights analyst Sawyer May.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Dominari Holdings, Inc.

Indications

Systemic Lupus ErythematosusLupus Nephritis

Targets

Drugs

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.